Immunic (IMUX) said Thursday it closed its direct offering of about 5.67 million shares at $0.90 apiece, led by Aberdeen Investments.
Immunic said it plans to use the proceeds for clinical trials, operations and general corporate purposes. American Capital Partners division, Titan Partners Group, was the placement agent.
Price: 0.89, Change: -0.04, Percent Change: -4.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.